Violich Capital Management Inc. Trims Stock Position in Kenvue Inc. $KVUE

Violich Capital Management Inc. cut its stake in shares of Kenvue Inc. (NYSE:KVUE) by 16.2% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 30,252 shares of the company’s stock after selling 5,862 shares during the period. Violich Capital Management Inc.’s holdings in Kenvue were worth $633,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in KVUE. Pittenger & Anderson Inc. purchased a new stake in Kenvue during the 1st quarter valued at approximately $30,000. Trust Co. of Vermont lifted its holdings in shares of Kenvue by 266.8% in the 2nd quarter. Trust Co. of Vermont now owns 1,581 shares of the company’s stock valued at $33,000 after buying an additional 1,150 shares during the period. TruNorth Capital Management LLC acquired a new stake in shares of Kenvue in the 1st quarter valued at approximately $36,000. Truvestments Capital LLC acquired a new stake in shares of Kenvue in the 1st quarter valued at approximately $37,000. Finally, Clal Insurance Enterprises Holdings Ltd lifted its holdings in shares of Kenvue by 378.5% in the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 1,627 shares of the company’s stock valued at $39,000 after buying an additional 1,287 shares during the period. 97.64% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research firms have recently commented on KVUE. Redburn Partners set a $22.00 price target on Kenvue in a report on Friday, September 26th. The Goldman Sachs Group reduced their price target on Kenvue from $22.00 to $19.00 and set a “neutral” rating for the company in a report on Thursday, October 2nd. JPMorgan Chase & Co. reduced their price target on Kenvue from $24.00 to $21.00 and set an “overweight” rating for the company in a report on Friday, October 10th. Canaccord Genuity Group reduced their price target on Kenvue from $29.00 to $26.00 and set a “buy” rating for the company in a report on Friday, August 8th. Finally, Rothschild Redb raised Kenvue from a “hold” rating to a “strong-buy” rating in a research note on Friday, September 26th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, nine have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Kenvue currently has an average rating of “Hold” and an average target price of $21.18.

Kenvue Stock Performance

NYSE KVUE opened at $15.30 on Friday. The business has a 50 day moving average price of $18.54 and a 200 day moving average price of $21.04. The company has a market capitalization of $29.37 billion, a P/E ratio of 20.68, a PEG ratio of 2.20 and a beta of 0.72. The company has a debt-to-equity ratio of 0.66, a current ratio of 0.98 and a quick ratio of 0.68. Kenvue Inc. has a 1-year low of $14.05 and a 1-year high of $25.17.

Kenvue (NYSE:KVUE) last announced its earnings results on Thursday, August 7th. The company reported $0.29 EPS for the quarter, beating analysts’ consensus estimates of $0.28 by $0.01. The firm had revenue of $3.84 billion for the quarter, compared to analysts’ expectations of $3.94 billion. Kenvue had a return on equity of 20.06% and a net margin of 9.37%.Kenvue’s quarterly revenue was down 4.0% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.32 EPS. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. Sell-side analysts expect that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Wednesday, August 27th. Shareholders of record on Wednesday, August 13th were issued a dividend of $0.2075 per share. This is a boost from Kenvue’s previous quarterly dividend of $0.21. The ex-dividend date was Wednesday, August 13th. This represents a $0.83 dividend on an annualized basis and a yield of 5.4%. Kenvue’s payout ratio is currently 112.16%.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.